Glaxosmithkline Pharmaceuticals Ltd share price logo

Glaxo Share Price (GLAXO)

₹2772.67.1%

as on

| Source : NSE

bell
The current prices are delayed by 15 mins, login to check live prices.

Glaxo Stock Performance

as on August 13, 2025 at 4:01 PM IST

  • Day's Low

    Day's High

    ₹2,597.9
    ₹2,789
    downward going graph

    6.30%

    Downside

    0.59%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    ₹1,921
    ₹3,515.7
    downward going graph

    30.71%

    Downside

    26.80%

    Upside

    downward going graph
Previous Close₹2,588.70
Open₹2,605.00
Volume4.21L
Upper Circuit₹3,106.40
Lower Circuit₹2,071.00
Day's Low2,597.9
Day's High2,789
52 Week Low1,921
52 Week High3,515.7
1 Month Return-18.8 %
3 Month Return-7.17 %
1 Year Return-8.4 %
3 Year Return+ 78.53 %
5 Year Return+ 69.85 %

Glaxo Stock Fundamentals & Key Indicators

Check Glaxo market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

₹43,854.14 Cr

Return on Equity (ROE)

49.23

PE Ratio (TTM)

46.34

Return on capital employed (ROCE)

58.72

Industry PE ratio

42.49

Beta (LTM)

0.79

P/B Ratio

25.01

Dividend Yield

1.88

PEG Ratio

4.21

Quarterly Earnings Growth YOY

12.44

EPS (TTM)

54.76

Sector

Pharmaceuticals

Book Value

115.19

Technical Analysis

Glaxo Stock's Interest Amongst Investors

2%

Period Aug 13, 2025 to Jul 14, 2025. Change in 30 Days vs previous period

Search interest for Glaxosmithkline Pharmaceuticals Ltd Stock has increased by 2% in the last 30 days, reflecting an upward trend in search activity.

Glaxo Stock Valuation

Track how Glaxo P/E has moved over time to understand its valuation trends.

Glaxo in the last 5 years

  • Overview

  • Trends

Lowest (-81.64x)

December 28, 2020

Industry (42.49x)

August 12, 2025

Today (46.34x)

August 12, 2025

Highest (333.07x)

September 15, 2020

LowHigh

Today’s Price to Earnings Ratio: 46.34x

Glaxo Stock Recommendation

Get updated buy, sell, and hold recommendations by analysts on Glaxo.

based on 4 analysts

BUY

50.00%

Buy

25.00%

Hold

25.00%

Sell

50% of analysts recommend a 'BUY' rating for Glaxo. Average target price of ₹3094.75

Source: S&P Global Market Intelligence

Glaxo Share Price Target

Get share price movements and forecasts by analysts on Glaxo.

Glaxo price forecast by 4 analysts

Upside of19.55%

High

₹3500

Target

₹3094.75

Low

₹2600

Glaxo target price ₹3094.75, a slight upside of 19.55% compared to current price of ₹2772.6. According to 4 analysts rating.

Source: S&P Global Market Intelligence

Glaxosmithkline Pharmaceuticals Ltd Financial Results

Get the annual and quarterly financial summary of Glaxosmithkline Pharmaceuticals Ltd, including revenue, profit, loss and more.

Value in ₹ crore
DetailsQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26
Revenue

(in ₹ Cr)

815 (0%)1011 (24%)949 (6%)974 (3%)805 (17%)
Net Income

(in ₹ Cr)

182 (0%)252 (38%)230 (9%)263 (14%)205 (22%)
Net Profit Margin22.38% (0%)24.98% (12%)24.21% (3%)26.98% (11%)25.46% (6%)
Value in ₹ crore
DetailsFY22FY23FY24FY25
Total Assets

(in ₹ Cr)

4652 (0%)3345 (28%)3574 (7%)4135 (16%)
Total Liabilities

(in ₹ Cr)

1989 (0%)1604 (19%)1796 (12%)2184 (22%)
Value in ₹ crore
DetailsFY21FY22FY23FY24FY25
Operating Cash Flow

(in ₹ Cr)

595 (0%)820 (38%)488 (40%)579 (19%)1280 (121%)

Glaxo Earnings and Dividends

View detailed summary of the earnings and dividend history of Glaxo.

  • Glaxosmithkline Pharmaceuticals Ltd Earnings Results

    Glaxosmithkline Pharmaceuticals Ltd’s net profit jumped 12.44% since last year same period to ₹205.01Cr in the Q1 2025-2026. On a quarterly growth basis, Glaxosmithkline Pharmaceuticals Ltd has generated -22.01% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Glaxosmithkline Pharmaceuticals Ltd Dividends May,2025

    In the quarter ending March 2025, Glaxosmithkline Pharmaceuticals Ltd has declared dividend of ₹42.00 per share on 13 May 2025 - translating a dividend yield of 3.20%.

    Read More about Dividends

Indices Featuring Glaxo Stock

Check stock indices that include Glaxo.

S&P BSE Quality

₹1,773.06

0.76 (13.4%)

BSE Mid-Cap

₹45,059.67

0.56 (249.79%)

BSE Healthcare

₹44,597.50

1.76 (772.62%)

S&P BSE 250 LargeMidCap

₹10,593.30

0.54 (57.03%)

Nifty 500

₹22,698.10

0.57 (129.5%)

S&P BSE 150 MidCap

₹15,621.71

0.53 (82.33%)

Nifty LargeMidcap 250

₹15,934.50

0.59 (93.5%)

BSE 500

₹35,631.91

0.55 (194.85%)

BSE 200

₹11,154.90

0.53 (58.52%)

Nifty Midcap 150

₹21,067.30

0.63 (132.1%)

S&P BSE 400 MidSmallCap

₹11,765.99

0.56 (66%)

Nifty MidSmallcap 400

₹19,513.55

0.63 (123.05%)

Glaxo Stock Shareholding Pattern

View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Glaxo.

InvestorsHoldings %Quarterly Trend3M change
Promoter Holdings
75%
0.00
Foreign Institutions
4.88%
8.10
Mutual Funds
5.17%
0.00
Retail Investors
12.41%
-2.21
Others
2.54%
-3.26

Glaxosmithkline Pharmaceuticals Ltd vs Peers

Compare market cap, revenue, PE, and other key metrics of Glaxo with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
BUY43,854.1413.97%0.569273,749
BUY11,729.18-7.56%0.524132,013
BUY62,004.024.01%0.593,16829,001
HOLD96,160.7529.46%0.614,61423,241
BUY69,190.0019.06%0.001,4146,445

Glaxo News & Key Events

Latest news and events in one place to help you make informed investing decisions in Glaxo.

  • GSK Pharma Faces Revenue Decline Amid Profit Growth - 01 Aug, 2025

    GSK Pharma reported its first revenue decline in over two years, leading to a 5.5% drop in shares. However, net profit rose 12.44% to Rs 205.01 crore. The company is set to launch oncology products Jemperli and Zejula, addressing critical cancer treatment needs.
  • GlaxoSmithKline Focuses on Innovation and Growth - 25 Jul, 2025

    GlaxoSmithKline Pharmaceuticals emphasizes innovation, strong financials, and operational excellence. Key metrics indicate a buy recommendation at ₹3,156, targeting ₹3,560 in 2-3 months, with a stop loss at ₹2,990.

Insights on Glaxosmithkline Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 4.52% to 4.88% in Jun 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 22.6% return, outperforming this stock by 31.0%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 75.00% of holdings in Jun 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 130.4% return, outperforming this stock by 51.9%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 12.69% to 12.41% in Jun 2025 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 1.01K Cr → 848.89 Cr (in ₹), with an average decrease of 16.4% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, GLAXO stock has moved down by -18.8%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 262.87 Cr → 205.01 Cr (in ₹), with an average decrease of 22.0% per quarter

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UKbased GSK Plc. a global biopharma company to unite science technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices a manufacturing facility at Nashik in Maharashtra 22 contract manufacturing organisations CMOs with regional and sales hubs across India. The Company is engaged interalia in the business of manufacturing distributing and trading in pharmaceuticals.The Companys portfolio includes General Medicines Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas such as AntiInfectives Dermatology Gynaecology Diabetes Oncology Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines for the prevention of Hepatitis A Hepatitis B Invasive Disease caused by H Influenza Chickenpox Diphtheria Pertussis Tetanus Rotavirus Cervical Cancer and Others. They have two manufacturing units in India located at Nashik and Thane. Also they have a clinical development centre in Bangalore. GlaxoSmithKline Pharma Limited was incorporated in November 13 1924. During year 1956 the Company began primary production of vaccines at Worli. In the year 1960 the company started manufacturing Infant foods at milk drying plant at Aligarh. They also opened manufacturing facility for pharmaceuticals in Mumbai. In 1961 the Company started manufacturing Vitamin A and Betamethasone at new plant at Thane using imported raw materials. The Company registered as a limited company in the year 1968. Also they introduced the Animal health products. In the year 1971 the company built the Research development laboratory at Thane. Also they relocated the SmithKline French plant from Mumbai to Bangalore. In the year 1983 they commissioned the Nashik factory. SmithKline Beecham became a public limited company under the new name of Eskayef Ltd in the year 1984 and one new Plant was set up in Mysore for manufacture of bulk drugs. In the year 1985 the companys second basic drugs factory was inaugurated at Ankleshwar Gujarat. In the year 1986 the company launched joint venture projects Vegepro Foods and Feeds Ltd and K G Gluco Biols. The companys name was changed to Glindia Ltd in the year 1987. In the year 1988 the company commenced the production of bulk drug Ranitidine at Ankleshwar. Also they started a joint venture project with Hindustan Foods Ltd for the manufacture of extruded foods at Usgao Goa. In the year 1989 the company commenced their Zinetac production at Nashik. The companys name was changed from Glindia Ltd to Glaxo India Ltd. In the year 1990 the production of the bulk drug cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik. Glaxo rated amongst the first five of Indias most respected companies 4th place in a survey by Businessworld magazine. An agreement was signed with the Council of Scientific and Industrial Research CSIR during 1991. In the year 1992 the company sold their trade investments in Vegepro and Feeds Ltd. In the year 1993 they sold their investment in Hindustan Foods Ltd and Dempo Dairy Industries Ltd. Cetzine a secondgeneration antihistamine and research product of UCB Pharma Belgium was launched under a comarketing agreement. In the same year Glaxo received recognition from the Ministry of Commerce as an export house. In the year 1994 the company sold their Family Products Division to H J Heinz for a sum of Rs 210 crore. The Mysore plant received ISO 9002 certification and the new Iodex plant was inaugurated in Bangalore. In the year 1995 they inaugurated the government approved stateoftheart Pharmacy Research Development Centre PRD at Thane to cater to the unmet medical needs and to exploit local commercial opportunities.In the year 1998 the company acquired Biddle Sawyer Group of Companies which was struggled in the year before. In the year 2000 Agrivet Farm Care AFC tied up with Merial the worlds largest Animal Health Company to market poultry vaccines. The company ranked 6th in Business Today Stern Stewart Co. listing of Indias best Wealth Creator Companies and also the launched Seretide for Asthma. The merger of SmithKline Beecham Pharmaceuticals India Ltd into Glaxo India Limited was completed and the name of the company was changed to the present name GlaxoSmithKline Pharmaceuticals Ltd. Businessworld and the Indian Market Research Bureau IMRB named GlaxoSmithKline as Indias most respected Pharmaceutical Company in a survey in the year 2003. During the year the company launched Cetzine Cetirizine antihistamine Zimig terbinafine antiinfective CCM calcium citrate maleate nutritional Cobadex CZS multivitamin with trace elements.In the year 2004 the company launched Priorix measles mumps rubella vaccine. In the year 2005 the company launched oral contraceptives: Elogen desogestrel and ethinylestradiol and Zerogen progesterone only pill. They entered into the diabetes therapeutic segment with the launch of Windia rosiglitazone and Windamet rosiglitazone and metformin. In the year 2006 the company made an inlicensing alliance with Eisai Pharmaceuticals Japan and launched Parit rabeprazole gastrointestinal therapy area. Also GlaxoSmithKline divested their Agrivet Farm Care AFC animal health business. In the year 2007 the company launched Carzec carvedilol and Zemetril cefprozil.

Revenue: ₹805.17Cr as on June 2025 (Q1 FY26)
Net Profit: ₹205.01Cr as on June 2025 (Q1 FY26)
Listing date: 03 Nov, 1994
Chairperson Name: Renu S Karnad
OrganisationGlaxosmithkline Pharmaceuticals Ltd
IndustryPharmaceuticals
CEORenu S Karnad
E-voting on sharesClick here to vote

FAQs

What is Glaxo share price today?

Glaxo share price today stands at ₹2772.6, Open: ₹2605, Previous Close: ₹2588.7, High: ₹2789, Low: ₹2597.9, 52 Week High: ₹3515.7, 52 Week Low: ₹1921 as on .

How to buy Glaxo shares ?

To buy Glaxo shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for GLAXO or Glaxosmithkline Pharmaceuticals Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Glaxo shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is today's traded volume of Glaxo?

Today's traded volume of Glaxo is 4.21L. Which means that 4.21L shares of Glaxo were bought and sold on the stock market during today's trading session.

What is Glaxo's market cap today?

Today's market capitalisation of Glaxo is ₹43,854.14 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.

What is the 52 week high and 52 week low range of Glaxo?

Glaxo’s 52 week high is ₹3515.7 and 52 week low is ₹1921. The current share price of Glaxo is ₹2772.6, which is -21.14% down from its 52 week high and 44.33% up from its 52 week low.